Business and Asset Acquisitions (Tables)

9 Months Ended

Sep. 30, 2018

PhotoMedex [Member]

Schedule of Pro Forma Financial Information

	For the three months ended September 30,						For the nine months ended September 30,
	2018			2017			2018			2017
Net sales	$	5,483,909		$	7,559,754		$	21,466,771		$	26,695,949
Net loss	$	(1,293,637	)	$	(2,356,103	)	$	(2,012,136	)	$	(3,858,089	)
Net loss per share – basic and diluted	$	(0.02	)	$	(0.05	)	$	(0.04	)	$	(0.08	)
Weighted average number of common shares basic and diluted		53,132,004			52,321,826			52,633,008			49,518,478

Ermis Labs [Member]

Schedule of Deferred Consideration

The changes in the Company’s deferred consideration payable due to Ermis Labs, Inc. during the nine months ended September 30, 2018:

Balance at December 31, 2017	$	1,212,067
Consideration payments		(160,414	)
Accretion of interest		70,527
Balance at September 30, 2018-related party	$	1,122,180
Current portion	$	86,392
Non-current portion		1,035,788
	$	1,122,180